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Evaluation of the homocysteine assay on the ABBOTT IMX 





Hyperhomocysteinemia is considered as a powerful independent risk factor for 
atherosclerotic vascular disease. We evaluated an automated immunoassay for 
measuring homocysteine (HCY) concentrations in serum or plasma (IMx ABBOTT 
Laboratories). The biochemical principle of the assay consists of a reduction of HCY 
bound to albumin and to other small molecules by DTT, followed by an enzymatic 
conversion of the HCY to Sadenosyl-L-homocysteine (SAH). In subsequent steps, the 
specific monoclonal antibody and the fluorescently labelled SAH analog tracer 
constitute the fluorescence polarization immunoassay (FPIA) detection system. 
 
The new assay showed good precision at all concentration levels, e.g. intra-assay CV’s of 
1.3 to 1.6% for HCY concentrations of 13.5 to 26.1 µmol/l (n=20) and inter-assay CV’s of 
1.5 to 2.0% for the same sample (n=10). Serial dilutions of plasma samples with elevated 
HCY content exhibited good linearity. Lipemic, haemolytic and icteric samples showed no 
interference. Two samples of normal plasma were spiked with kit calibrator (50µmol/L) 
at 1:1, 2:1, and 5:1 ratio, respectively. The recovery rates of the spike samples were 
between 99% to 101%. Excellent agreement to results was obtained in comparison to 
HPLC technique (Bio-Rad Laboratories): y (IMx) = 1.07 x (HPLC) + 0.2, r=0.98, n=43. In 
conclusion, we have validated a rapid, accurate, precise and automated method for 
quantifying total HCY. 
